Perspectives of healthcare providers and patients with relapsed/refractory multiple myeloma on treatment priorities and novel therapies

This study surveyed over 2200 patients and HCPs on relapsed/refractory multiple myeloma. It revealed gaps in treatment priorities: patients valued quality of life and AE management, while HCPs focused on survival and disease control. Logistical challenges hinder novel therapy access. The findings emphasize the need for shared decision-making education.